Pathy's Principles and Practice of Geriatric Medicine. Группа авторов
Чтение книги онлайн.
Читать онлайн книгу Pathy's Principles and Practice of Geriatric Medicine - Группа авторов страница 208
![Pathy's Principles and Practice of Geriatric Medicine - Группа авторов Pathy's Principles and Practice of Geriatric Medicine - Группа авторов](/cover_pre1070388.jpg)
36 36. Sandler RS, Nyren O, Ekbom A, Eisen GM, Yuen J, Josefsson S. The risk of esophageal cancer in patients with achalasia. A population‐based study. Jama.1995; 274(17):1359–1362.
37 37. Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015; 27(2):160–174.
38 38. Zarowitz BJ. Pharmacologic consideration of commonly used gastrointestinal drugs in the elderly. Gastroenterol Clin North Am. 2009; 38(3):547–562.
39 39. Matsumoto Y, Senda E, Yamada H. Dabigatran‐induced esophagitis associated with vomiting. Am J Gastroenterol. 2019; 114(4):548.
40 40. Eslick GD, Fass R. Noncardiac chest pain: evaluation and treatment. Gastroenterol Clin North Am. 2003; 32(2):531–552.
41 41. George N, Abdallah J, Maradey‐Romero C, Gerson L, Fass R. Review article: the current treatment of non‐cardiac chest pain. Aliment Pharmacol Ther. 2016; 43(2):213–239.
42 42. Eslick GD, Talley NJ. Natural history and predictors of outcome for non‐cardiac chest pain: a prospective4‐year cohort study. Neurogastroenterol Motil. 2008; 20(9):989–997.
43 43. Achem SR, DeVault KR. Gastroesophageal reflux disease and the elderly. Gastroenterol Clin North Am. 2014; 43(1):147–160.
44 44. Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton‐pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017; 8(9):273–297.
45 45. Malfertheiner P, Kandulski A, Venerito M. Proton‐pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017; 14(12):697–710.
46 46. Pham H, Phillips L, Trahair L, Hatzinikolas S, Horowitz M, Jones KL. Longitudinal changes in the blood pressure responses to, and gastric emptying of, an oral glucose load in healthy older subjects. J Gerontol A Biol Sci Med Sci. 2019.
47 47. Gidal BE. Drug absorption in the elderly: biopharmaceutical considerations for the antiepileptic drugs. Epilepsy Res. 2006; 68 Suppl1:S65‐69.
48 48. Soenen S, Rayner CK, Horowitz M, Jones KL. Gastric emptying in the elderly. Clin Geriatr Med. 2015; 31(3):339–353.
49 49. Camilleri M, Chedid V, Ford AC, et al. Gastroparesis. Nat Rev Dis Primers. 2018; 4(1):41.
50 50. Fich A, Camilleri M, Phillips SF. Effect of age on human gastric and small bowel motility. J Clin Gastroenterol.1989; 11:416–420.
51 51. Serra‐Prat M, Mans E, Palomera E, Clave P. Gastrointestinal peptides, gastrointestinal motility, and anorexia of aging in frail elderly persons. Neurogastroenterol Motil. 2013; 25(4):291–e245.
52 52. Visvanathan R, Chapman IM. Undernutrition and anorexia in the older person. Gastroenterol Clin North Am. 2009; 38(3):393–409.
53 53. Salles N. Basic mechanisms of the aging gastrointestinal tract. Dig Dis. 2007; 25(2):112–117.
54 54. Husebye E, Engedal K. The patterns of motility are maintained in the human small intestine throughout the process of aging. Scand J Gastroenterol.1992; 27:397–404.
55 55. Mitsui T, Kagami H, Kinomoto H, Ito A, Kondo T, Shimaoka K. Small bowel bacterial overgrowth and rice malabsorption in healthy and physically disabled older adults. J Hum Nutr Diet. 2003; 16(2):119–122.
56 56. Schiller LR. Diarrhea and malabsorption in the elderly. Gastroenterol Clin North Am. 2009; 38(3):481–502.
57 57. Thomson AB. Small intestinal disorders in the elderly. Best Pract Res Clin Gastroenterol. 2009; 23(6):861–874.
58 58. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009; 18(3):349–358.
59 59. Trahair LG, Horowitz M, Jones KL. Postprandial hypotension: a systematic review. J Am Med Dir Assoc. 2014; 15(6):394–409.
60 60. Jones KL, Rigda RS, Buttfield MDM, et al. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. Diabetes Obes Metab. 2019; 21(5):1158–1167.
61 61. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2003;2( 2):107–116.
62 62. Natale G, Pasquali L, Ruggieri S, Paparelli A, Fornai F. Parkinson’s disease and the gut: a well known clinical association in need of an effective cure and explanation. Neurogastroenterol Motil. 2008; 20(7):741–749.
63 63. Leow LP, Huckabee ML, Anderson T, Beckert L. The impact of dysphagia on quality of life in ageing and Parkinson’s disease as measured by the swallowing quality of life (SWAL‐QOL) questionnaire. Dysphagia. 2010; 25(3):216–220.
64 64. Leow LP, Beckert L, Anderson T, Huckabee ML. Changes in chemosensitivity and mechanosensitivity in aging and Parkinson’s disease. Dysphagia. 2012; 27(1):106–114.
65 65. Heetun ZS, Quigley EM. Gastroparesis and Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2012; 18(5):433–440.
66 66. Du YT, Rayner CK, Jones KL, Talley NJ, Horowitz M. Gastrointestinal symptoms in diabetes: prevalence, assessment, pathogenesis, and management. Diabetes Care. 2018; 41(3):627–637.
67 67. Kuo P, Rayner CK, Horowitz M. Gastric emptying, diabetes, and aging. Clin Geriatr Med. 2007; 23(4):785–808, vi.
68 68. Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 2013; 36(5):1396–1405.
69 69. Watson LE, Xie C, Wang X, et al. Gastric emptying in patients with well‐controlled type 2 diabetes compared with young and older control subjects without diabetes. J Clin Endocrinol Metab. 2019; 104(8):3311–3319.
70 70. Coleski R, Anderson MA, Hasler WL. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Dig Dis Sci. 2009.
71 71. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006; 23(6):691–712.
72 72. Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case‐control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006; 55(12):1697–1703.
73 73. Watson DI, Jamieson GG, Bessell JR, Devitt PG. Laparoscopic fundoplication in patients with an aperistaltic esophagus and gastroesophageal reflux. Dis Esophagus. 2006; 19(2):94–98.
74 74. Agrawal A, Khan MH, Whorwell PJ. Irritable bowel syndrome in the elderly: An overlooked problem? Dig Liver Dis. 2009; 41(10):721–724.
75 75. Drossman DA, Hasler WL. Rome IV‐Functional GI disorders: disorders of gut‐brain interaction. Gastroenterology. 2016; 150(6):1257–1261.
76 76. Brummond NR, Locke GR, 3rd, Choung RS, et al. Effects of birth cohorts on the irritable bowel syndrome support early‐life risk factors. Dig Dis Sci. 2015; 60(7):2112–2118.
77 77. Locke GR,3rd, Yawn BP, Wollan PC, Melton LJ,3rd, Lydick E, Talley NJ. Incidence of a clinical diagnosis